Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Connor, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connor, G. S.
Related Collections
Right arrow All Movement Disorders
Right arrow Tremor
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
Right arrow Antiepileptic drugs

Neurology 2002;59:132-134
© 2002 American Academy of Neurology
Brief Communications

A double-blind placebo-controlled trial of topiramate treatment for essential tremor

Gregory S. Connor, MD

From the Headache and Neurological Center of Oklahoma, Tulsa, OK.

Address correspondence and reprint requests to Gregory S. Connor, MD, Headache and Neurological Center of Oklahoma, Inc., 6585 South Yale, Suite 620, Tulsa, OK 74136.

The safety and efficacy of topiramate (400 mg/d or maximum tolerated dose) as monotherapy or adjunctive treatment of essential tremor were investigated in a placebo-controlled, crossover study (n = 24). Topiramate resulted in significantly greater reductions from baseline based on normalized scores for a clinical rating of tremor location/severity, specific motor tasks/functional disabilities, and tremor-resultant functional disabilities. Most common adverse events were appetite suppression/weight loss and paresthesias.




This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
J. J. Chen and D. M. Swope
Essential Tremor
Journal of Pharmacy Practice, December 1, 2007; 20(6): 458 - 468.
[Abstract] [PDF]

Home page
 NeurologyHome page
W. G. Ondo, J. Jankovic, G. S. Connor, R. Pahwa, R. Elble, M. A. Stacy, W. C. Koller, L. Schwarzman, S. -C. Wu, J. F. Hulihan, et al.
Topiramate in essential tremor: A double-blind, placebo-controlled trial
Neurology, March 14, 2006; 66(5): 672 - 677.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
R Bhidayasiri
Differential diagnosis of common tremor syndromes
Postgrad. Med. J., December 1, 2005; 81(962): 756 - 762.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. Raskin, P. D. Donofrio, N. R. Rosenthal, D. J. Hewitt, D. M. Jordan, J. Xiang, and A. I. Vinik
Topiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects
Neurology, September 14, 2004; 63(5): 865 - 873.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. D. Silberstein, W. Neto, J. Schmitt, and D. Jacobs
Topiramate in Migraine Prevention: Results of a Large Controlled Trial
Arch Neurol, April 1, 2004; 61(4): 490 - 495.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. L. Brandes, J. R. Saper, M. Diamond, J. R. Couch, D. W. Lewis, J. Schmitt, W. Neto, S. Schwabe, and D. Jacobs
Topiramate for Migraine Prevention: A Randomized Controlled Trial
JAMA, February 25, 2004; 291(8): 965 - 973.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
T. S. Edgar
Oral Pharmacotherapy of Childhood Movement Disorders
J Child Neurol, January 1, 2003; 18(1_suppl): S40 - S49.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.